Skip to Content
Merck
CN

SML4212

JQKD82 dihydrochloride

≥98% (HPLC), powder, Histone Demethylase Inhibitor

Synonym(s):

2,4-Bis(1-methylethoxy)phenyl 2-[[[2-[[2-(dimethylamino)ethyl]ethylamino]-2-oxoethyl]amino]methyl]-4-pyridinecarboxylate dihydrochloride, JQKD 82 dihydrochloride, JQKD-82 dihydrochloride

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

Empirical Formula (Hill Notation):
C27H40N4O5·2HCl
CAS Number:
Molecular Weight:
573.55
NACRES:
NA.21
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
Storage condition:
desiccated
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

SMILES string

O=C(C1=CC(CNCC(N(CCN(C)C)CC)=O)=NC=C1)OC2=CC=C(C=C2OC(C)C)OC(C)C.Cl.Cl

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

H2O: 2 mg/mL, clear

storage temp.

-10 to -25°C

Quality Level

General description

JQKD82 dihydrochloride is histone H3K4 demethylase inhibitor is a produg of KDM5-C49 phenol ester prodrug that selectively upregulates H3K4me3 and inhibits KDM5-dependent cancer growth.
(KDOAM-21; KDM5A/B/C/D Ki = 2/1/6.1/3.4 nM vs. KDM4C/6B/3A/2A Ki =0.51/4.55/2.59/4.4 μM; KDM5A/B/C/D IC50 = 1.1/0.8/3.2/2.7 μM by FDH assay with[αKG] = 1 mM & [E]/[S] = 0.5/15 μM; KDM5A/B/C IC50 = 25/30/59 nM by alphaLISA with [αKG] = 25 μM & [E]/[S] = 10/100 nM). JQKD82 selectively upregulates cellular histone H3K4me3 with a higher efficacy than KDM5-C49 orKDM5-C70 (3 μM for 24 h; MM.1S cells), and inhibits myeloma growth in cultures (MM.1S IC50 = 0.42 μM vs IC50 3.1 μM/KDM5-C70, >10 μM/KDM5-C49) and in vivo (50 mg/kg b.i.d. i.p. to mice with MOLP-8 xenograft).

Application

JQKD82 dihydrochloride may be used:
  • to study its effects on lysine demethylase 5A (KDM5A) function in multiple myeloma research
  • as a potential agent in HIV-1 research, where it was evaluated for its ability to reactivate latent HIV-1 inT cells
  • to study its effects on cell cycle arrest and apoptosis induction

Biochem/physiol Actions

A selective and cell-permeable lysine demethylase 5(KDM5) inhibitor.

Disclaimer

Hygroscopic

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Hiroto Ohguchi et al.
Blood cancer discovery, 2(4), 370-387 (2021-07-15)
Lysine demethylase 5A (KDM5A) is a negative regulator of histone H3K4 trimethylation, a histone mark associated with activate gene transcription. We identify that KDM5A interacts with the P-TEFb complex and cooperates with MYC to control MYC targeted genes in multiple
Rashmi Srivastava et al.
Epigenomes, 7(2) (2023-05-23)
Epigenetic modifications are heritable, reversible changes in histones or the DNA that control gene functions, being exogenous to the genomic sequence itself. Human diseases, particularly cancer, are frequently connected to epigenetic dysregulations. One of them is histone methylation, which is
Tai-Wei Li et al.
Antiviral research, 228, 105947-105947 (2024-06-27)
Combinational antiretroviral therapy (cART) suppresses human immunodeficiency virus type 1 (HIV-1) viral replication and pathogenesis in acquired immunodeficiency syndrome (AIDS) patients. However, HIV-1 remains in the latent stage of infection by suppressing viral transcription, which hinders an HIV-1 cure. One

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service